ArticleCureus2026

Comparative Cardiovascular Pharmacovigilance of Semaglutide and Tirzepatide: A Food and Drug Administration Adverse Event Reporting System (FAERS) Database Analysis (2022-2026).

Abhinandan Singla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.